Latest posts

Forum Statistics

Threads
27,639
Posts
542,808
Members
28,583
Latest Member
jacobss
What's New?

Interesting data!

CFM

CFM

National Breast Implant Awareness Month Squeezer
Mar 18, 2012
2,009
1,717
Testosterone Formulation​
Dosing Regimen​
(N)​
Rate of Erythrocytosis (>50%)​
Mean. T level (ng/dL) (converted units)​
Reference​
T enanthate and cypionate (short acting IM)​
100–200 mg IM qW​
57​
66.7%​
306 ± 164​
70
T undecanoate (extended release IM)​
1g q6 wks x3, then 1g q9 wks​
347​
7%​
467 ± 32​
78
Transdermal (Testim® gel, Androgel® 1.62%)​
50–100 mg T, one to two packets applied to the shoulder area daily (Testim® gel), 20.25–80.1 mg T, two to four pumps applied to the skin daily (Androgel®)​
47​
12.8%​
300 ± 89​
70
Oral testosterone undecanoate​
N/A​
1343​
0.003% (Hct>52%)​
N/A​
77​
Testosterone pellets​
75 mg crystalline T/pellet implanted with 10–14 pellets q 3–6 months​
74​
35.1%​
268 ± 167​
70

I for one find it hard to believe 66.7% vs 7% difference "rate" of Erythrocytosis between line 1 and line 2.
 
Last edited:
Who is viewing this thread?

There are currently 0 members watching this topic

Top